当前位置:首页 - 行情中心 - 昭衍新药(603127) - 财务分析 - 现金流量表

昭衍新药

(603127)

  

流通市值:267.22亿  总市值:319.00亿
流通股本:6.28亿   总股本:7.49亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,240,212,877.88548,028,113.11,772,381,774.151,273,147,554.37
  收到的税费返还1,872,280.83975,507.757,291,392.166,368,337.79
  收到其他与经营活动有关的现金14,419,854.357,844,283.1952,454,155.5443,956,095.03
  经营活动现金流入小计1,256,505,013.06556,847,904.041,832,127,321.851,323,471,987.19
  购买商品、接受劳务支付的现金358,573,410.34181,582,001.45567,303,820.73401,692,918.2
  支付给职工以及为职工支付的现金357,398,095.63207,289,895.12658,177,529.56528,437,549.04
  支付的各项税费43,523,614.1822,622,089.9363,156,061.1752,826,422.99
  支付其他与经营活动有关的现金39,795,994.0517,742,754.4698,923,188.2674,123,947.64
  经营活动现金流出小计799,291,114.2429,236,740.961,387,560,599.721,057,080,837.87
  经营活动产生的现金流量净额457,213,898.86127,611,163.08444,566,722.13266,391,149.32
二、投资活动产生的现金流量:
  收回投资收到的现金2,459,572,001.691,415,062,758.672,276,223,325.911,903,795,691.67
  取得投资收益收到的现金46,010,480.0522,020,747.9575,133,433.2462,042,621.85
  处置固定资产、无形资产和其他长期资产收回的现金净额16,81813,2501,361,360.161,145,178.46
  收到的其他与投资活动有关的现金--17,793,632.08-
  投资活动现金流入小计2,505,599,299.741,437,096,756.622,370,511,751.391,966,983,491.98
  购建固定资产、无形资产和其他长期资产支付的现金401,373,968.13369,283,452.94143,602,144.53121,121,329.56
  投资支付的现金2,596,690,277.781,110,000,0002,646,102,552.692,110,584,774.91
  投资活动现金流出小计2,998,064,245.911,479,283,452.942,789,704,697.222,231,706,104.47
  投资活动产生的现金流量净额-492,464,946.17-42,186,696.32-419,192,945.83-264,722,612.49
三、筹资活动产生的现金流量:
  吸收投资收到的现金50,221,515---
  筹资活动现金流入平衡项目0---
  筹资活动现金流入小计50,221,515---
  分配股利、利润或偿付利息支付的现金75,261,491.28-22,385,22922,385,229
  支付其他与筹资活动有关的现金10,586,143.365,447,459.8244,598,826.3136,603,316.91
  筹资活动现金流出小计85,847,634.645,447,459.8266,984,055.3158,988,545.91
  筹资活动产生的现金流量净额-35,626,119.64-5,447,459.82-66,984,055.31-58,988,545.91
四、汇率变动对现金及现金等价物的影响-17,041,736.06-8,746,427.18-11,738,509.02-5,822,610.67
五、现金及现金等价物净增加额-87,918,903.0171,230,579.76-53,348,788.03-63,142,619.75
  加:期初现金及现金等价物余额911,854,340.56911,854,340.56965,203,128.59965,203,128.59
  期末现金及现金等价物余额823,935,437.55983,084,920.32911,854,340.56902,060,508.84
补充资料:
  净利润747,518,791.03-297,842,526.3-
  资产减值准备20,145,063.73-156,760,636.98-
  固定资产和投资性房地产折旧45,879,734.93-94,903,390.14-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧45,879,734.93-94,903,390.14-
  无形资产摊销8,297,830.24-17,422,245.12-
  长期待摊费用摊销9,025,871.67-19,269,954.04-
  递延收益摊销-4,693,668.89-4,818,186.92-
  处置固定资产、无形资产和其他长期资产的损失---413,517.67-
  固定资产报废损失300,589.48-461,919.3-
  公允价值变动损失-838,035,702.05--447,560,334.54-
  财务费用-15,425,543.29--53,994,754.17-
  投资损失-5,584,385.22--18,013,906.02-
  递延所得税47,475,091.52-119,241.75-
  其中:递延所得税资产减少3,899,055.52--6,320,664.55-
    递延所得税负债增加43,576,036-6,439,906.3-
  存货的减少2,049,142.06-214,517,124.57-
  经营性应收项目的减少20,172,179.83-62,295,986.6-
  经营性应付项目的增加396,399,386.59-68,228,112.06-
  现金的期末余额823,935,437.55-911,854,340.56-
  减:现金的期初余额911,854,340.56-965,203,128.59-
  现金及现金等价物的净增加额-87,918,903.01--53,348,788.03-
公告日期2026-08-292026-04-302026-03-312025-10-31
审计意见(境内)标准无保留意见
TOP↑